Hawaii Biotech, a biopharmaceutical company focused on small molecules with anti-flammatory activity and targeted, rapid response to emergency disease and bioterrorism, received $15.5 million from the National Institutes of Health
(NIH) in separate grants.
Funds will be used for pre-clinical development of Hawaii Biotech's west nile virus and dengue vaccines and for its phase-one human clinical trial for the dengue vaccine.
Hawaii Biotech is located in Honolulu, Hawaii.
Lead Source: Business Wire
Recent Comments